Algeta & Bayer in cancer drug deal - Pharmaceutical Executive


Algeta & Bayer in cancer drug deal

Algeta has entered into an agreement with Bayer for the development and commercialisation of its first-in-class Alpharadin which is currently in Phase III trials in men with hormone-refractory prostate cancer (HRPC) which has spread into bone.

The deal gives Algeta an option for up to 50% co-promotion with Bayer in the US under a profit-share arrangement. Bayer will commercialise the drug globally and pay royalties on net sales in markets where there is no co-promotion.

Algeta will receive an upfront payment of $61 million with further payments, that could bring the total to $800 million, being paid upon the completion of various milestones.


blog comments powered by Disqus

Serialization Summit
San Diego, CA
Feb. 27-28, 2014

Advances in Aseptic Processing
San Diego, CA
Mar. 10-12, 2014

ClinTech 2014
Cambridge, MA
Mar. 11-13 2014

Investigator-Initiated and
Sponsored Research (IISR)

Philadelphia, PA
Mar. 19-20 2014

See All Conferences >>

Click here